96 related articles for article (PubMed ID: 10634235)
1. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what.
Metman LV; Konitsiotis S; Chase TN
Mov Disord; 2000 Jan; 15(1):3-8. PubMed ID: 10634235
[No Abstract] [Full Text] [Related]
2. Mechanism of action of dopaminergic agents in Parkinson's disease.
Koller WC; Rueda MG
Neurology; 1998 Jun; 50(6 Suppl 6):S11-4; discussion S44-8. PubMed ID: 9633680
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease: mechanisms and models.
Dauer W; Przedborski S
Neuron; 2003 Sep; 39(6):889-909. PubMed ID: 12971891
[TBL] [Abstract][Full Text] [Related]
4. Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?
Rota S; Urso D; van Wamelen DJ; Leta V; Boura I; Odin P; Espay AJ; Jenner P; Chaudhuri KR
Transl Neurodegener; 2022 Oct; 11(1):43. PubMed ID: 36229860
[TBL] [Abstract][Full Text] [Related]
5. Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson's Disease: A Perspective Through Preclinical and Clinical Evidence.
Bandopadhyay R; Mishra N; Rana R; Kaur G; Ghoneim MM; Alshehri S; Mustafa G; Ahmad J; Alhakamy NA; Mishra A
Front Pharmacol; 2022; 13():805388. PubMed ID: 35462934
[TBL] [Abstract][Full Text] [Related]
6. The increased gray matter volumes of precentral gyri in Parkinson's disease patients with diphasic dyskinesia.
Zhi Y; Wang M; Yuan YS; Shen YT; Ma KW; Gan CT; Si QQ; Wang LN; Cao SW; Zhang KZ
Aging (Albany NY); 2019 Nov; 11(21):9661-9671. PubMed ID: 31699957
[TBL] [Abstract][Full Text] [Related]
7. Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson's Disease: An Open-Label Pilot Study.
Khlebtovsky A; Steiner I; Treves T; Djaldetti R
Clin Transl Sci; 2019 Nov; 12(6):586-590. PubMed ID: 31436382
[TBL] [Abstract][Full Text] [Related]
8. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
[TBL] [Abstract][Full Text] [Related]
9. Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.
LeWitt PA; Verhagen Metman L; Rubens R; Khanna S; Kell S; Gupta S
Clin Neuropharmacol; 2018; 41(2):47-55. PubMed ID: 29432286
[TBL] [Abstract][Full Text] [Related]
10. Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management.
Pandey S; Srivanitchapoom P
Ann Indian Acad Neurol; 2017; 20(3):190-198. PubMed ID: 28904447
[TBL] [Abstract][Full Text] [Related]
11. Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy.
Alcacer C; Andreoli L; Sebastianutto I; Jakobsson J; Fieblinger T; Cenci MA
J Clin Invest; 2017 Feb; 127(2):720-734. PubMed ID: 28112685
[TBL] [Abstract][Full Text] [Related]
12. Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications.
Cenci MA
Front Neurol; 2014; 5():242. PubMed ID: 25566170
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of GluN2A-containing N-methyl-D-aspartate receptors by 2-naphthoic acid.
Yu H; Popescu GK
Mol Pharmacol; 2013 Oct; 84(4):541-50. PubMed ID: 23873856
[TBL] [Abstract][Full Text] [Related]
14. Pathological tremor prediction using surface electromyogram and acceleration: potential use in 'ON-OFF' demand driven deep brain stimulator design.
Basu I; Graupe D; Tuninetti D; Shukla P; Slavin KV; Metman LV; Corcos DM
J Neural Eng; 2013 Jun; 10(3):036019. PubMed ID: 23658233
[TBL] [Abstract][Full Text] [Related]
15. Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease.
Lv Q; Zhang B
Neurosci Bull; 2013 Oct; 29(5):661-9. PubMed ID: 23512740
[TBL] [Abstract][Full Text] [Related]
16. Clinical aspects and management of levodopa-induced dyskinesia.
Tambasco N; Simoni S; Marsili E; Sacchini E; Murasecco D; Cardaioli G; Rossi A; Calabresi P
Parkinsons Dis; 2012; 2012():745947. PubMed ID: 22701811
[TBL] [Abstract][Full Text] [Related]
17. Current approaches to the treatment of Parkinson's disease.
Jankovic J; Aguilar LG
Neuropsychiatr Dis Treat; 2008 Aug; 4(4):743-57. PubMed ID: 19043519
[TBL] [Abstract][Full Text] [Related]
18. Levodopa-induced dyskinesias and their management.
Del Sorbo F; Albanese A
J Neurol; 2008 Aug; 255 Suppl 4():32-41. PubMed ID: 18821084
[TBL] [Abstract][Full Text] [Related]
19. Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias.
Konitsiotis S; Tsironis C; Kiortsis DN; Evangelou A
Psychopharmacology (Berl); 2006 Apr; 185(3):369-77. PubMed ID: 16518645
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Nyholm D
Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
